Adjuvant Chemotherapy for Patients with Locally Advanced Adenocarcinoma of the Large Bowel
Publication Information Expand/Collapse
1994
With > 4,600 patient-years follow-up, SWOG colorectal adjuvant study suggests that BCG may act as a chemoprevention agent.
1989
After resection of large bowel carcinoma, immune status is often depressed. Data from a SWOG study.
1988
Adjuvant therapy in large bowel adenocarcinoma: Long term resultsof a Southwest Oncology Group Study.
1986
The prognosis of exophytic large bowel tumors. Data from aSouthwest Oncology Group adjuvant study and the University of ArkansasMedical Science Campus.
1985
SWOG large bowel adjuvant study suggests benefits from therapy.
1984
SWOG large bowel postoperative program. An update.
1983
The SWOG large bowel adjuvant program. An update.
Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU)
Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU)
1982
The SWOG colon adjuvant study of chemotherapy with and without oral BCG: An update.
Long-term hematologic effects of Methyl-CCNU plus 5-FU given in a Southwest Oncology Group adjuvant study.
1981
Letter to the Editor: IgA antibody-dependent cellular cytotoxicity and prognosis in patients with nasopharyngeal carcinoma.
Analysis of 626 patients entered on the SWOG large bowel adjuvant program.
Update on the Southwest Oncology Group Colorectal Adjuvant study of 620 patients.
1980
The SWOG Colon Adjuvant Study of chemotherapy with and without oral BCG - an update.
Long-term effects of chemotherapy on leukocytes of clinically healthy patients treated in accordance with the Southwest Oncology Group Colon Adjuvant Protocol.
Adjuvant chemotherapy with or without immunotherapy in colorectal cancer.
1979
Effectiveness of post-operative adjuvant therapy with methyl-CCNU plus 5-FU with or without oral BCG in an attempt to prevent recurrence of Duke B-2 or C colon cancer. Interim report of a continuing SWOG study.
Race and chemotherapy-induced marrow suppression.
Are there racial differences in chemotherapy- induced leukocyte suppression.
Effectiveness of postoperative adjuvant therapy with Methyl CCNU + 5-FU with or without oral BCG in an attempt to prevent recurrence of Duke B2 or C Colon cancer, interim report of continuous SWOG studies.
1978
Postoperative adjuvant chemotherapy and immuno- therapy after total clinical resection of Duke C large bowel cancer: A Southwest Oncology Group study.
1977
Adjuvant therapy for locally advanced large bowel cancer.
Skin test reactivity in patients with high-risk but clinically totally resected large bowel cancer.
Adjuvant chemotherapy and chemoimmunotherapy for locally advanced large bowel adenocarcinoma. Preliminary report of a SWOG study.